长新冠病毒感染的研究进展

张斯 斯1, 石仲 玉2, 张风 林1, 喻昌 利2
1 唐山市人民医院 2 华北理工大学附属医院 河北唐山 063000

摘要

摘要：长新冠病毒感染(简称长新冠)通常指新冠后遗症。一般指在临床上处于新冠病毒感染恢复期的患者，通常在3个月后出现累及全身多系统多脏器的表现，如乏力、呼吸困难、认知障碍及失眠等症状，上述症状至少持续2个月，且没有其他明显的诱因来解释的征象。长新冠多累及肺部和全身其他器官，严重时患者可失去生活自理能力，对其心理健康造成严重影响。本文简要阐述长新冠主要发病机制和临床表现，总结长新冠的系统治疗方法，旨在提高和加深对长新冠的认识水平。

关键词

关键词：长新冠病毒感染；长新冠；发病机制；治疗

参考

[1] Wan EYF, Mathur S, Zhang R, Yan VKC, Lai FTT, Chui CSL, Li X, Wong CKH, Chan EWY, Yiu KH, Wong ICK. Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality： a prospective cohort in UK Biobank. Cardiovasc Res. 2023 Jul 6;119(8)：1718-1727. doi： 10.1093/cvr/cvac195. PMID： 36652991.[2]Shang J,Ye G,Shi K,et al. Structural basis of receptorrecognition by SARS- Co V- 2[J]. Nature,2020,581(7807)：221-224.[3]Harmer D,Gilbert M,Borman R,et al. Quantitative m RNAexpression profiling of ACE 2,a novel homologue of angiotensinconverting enzyme[J]. FEBS Lett,2002,532(1-2)：107-110.[4]SOLOMON J J, HEYMAN B, KO J P,et al. CT of Post-Acute Lung Complications of COVID-19[J]. Radiology, 2021, 301(2)： e383-e395.[5]Zhang JJ, Dong X, Cao YY,etc. Clinical characteristics of 140patients infected with SARS-Co V-2 in Wuhan, China. Allergy. 2020 Jul;75(7)：1730-1741. doi： 10.1111/all.14238. Epub 2020 Feb 27.[6]Wu Z, Mc Googan JM： Characteristics of and Important Lessons From theCoronavirus Disease 2019 (COVID-19) Outbreak in China： Summary of aReport of 72 314 Cases From the Chinese Center for Disease Controland Prevention. Jama 2020.[7]Shah W,Hillman T,Playford ED,et al. Managing the long termeffects of COVID-19：summary of NICE,SIGN,and RCGP rapidguideline[J]. BMJ,2021,372：n136.[8]Cares-Marambio K,Montenegro-Jimnez Y,Torres-Castro R,etal. Prevalence of potential respiratory symptoms in survivors ofhospital admission after coronavirus disease 2019(COVID-19)：asystematic review and meta- analysis [J]. Chron Respir Dis,2021,18：14799731211002240.[9]Ge Xing-Yi,Li Jia-Lu,Yang Xing-Lou, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor.[J]. Nature, 2013, 503(7477)：535-8.[10]MISHIMA E,ANAZAI N,MIYAZAKI M,et al.Uric acid elevation by favipiravir,an antiviral drug[J].Tohoku J Exp Med,2020,251( 2) ： 87-90.[11]Konstantinos Pontikis,Ilias Karaiskos,Styliani Bastani,etc.Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria[J].2014,43 (1).[12]Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China： a descriptive study. Lancet, 2020, 395(10223)：507-513.[13]中华预防医学会新型冠状病毒肺炎防控专家组.新型冠状病毒肺炎流行病学特征分析[J].中华流行病学杂志,2020,41(2)：139-144[14]Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). med Rxiv, 2020. [2020-02-21].[15]Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distresssyndrome [J/OL]. Lancet Respir Med, 2020(2020-2-8). https：//doi. org/10. 1016/S2213-2600(20)30076-X.[16]Xie LX, Liu YN, Hao FY, et al. Prognostic analysisof lung function and chest Xray changes of 258 patientswith severe acute respiratory syndrome in rehabilitationafter discharge [J]. Chinese Journal of Tuberculosis andRespiratory Diseases, 2004, 27(3)：147-150.[17]Chen X, Wu Y, Chen C, et al. Identifying potential antiCOVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening. Acta Pharm Sin B, 2021, 11(1)： 222-236.[18]李旷宇,安薇,夏飞等.肺排毒汤加减方联合抗病毒药物治疗新型冠状病毒肺炎的回顾性研究.中草药 http：//kns.cnki.net/kcms/detail/12.1108.R.20200407.1425.011.html.